Literature DB >> 10738132

Analysis of Fas and Fas ligand expression and function in lung cancer cell lines.

M Kawasaki1, K Kuwano, Y Nakanishi, N Hagimoto, K Takayama, X H Pei, T Maeyama, M Yoshimi, N Hara.   

Abstract

The aim of this study was to investigate the expression of Fas and Fas ligand (FasL) and to determine the significance of these molecules in lung cancer cell lines. Immunoblotting, RT-PCR and flow cytometric analyses were carried out to measure the expression of Fas and FasL and to examine their interactions and effects on cell growth and apoptosis. Fas and FasL were co-expressed in most of the cell lines but to varying degrees. Apoptosis induced by the agonistic anti-Fas antibody was significantly correlated with Fas expression (P=0.0075), whereas cisplatin-induced apoptosis was not. Upregulation of Fas and FasL expression by the administration of cisplatin was found in 7 of 11 (64%) and 9 of 11 (82%) cell lines, respectively. However, cisplatin-induced apoptosis was not suppressed by antagonistic anti-FasL antibody. Thus, our data indicated that Fas and FasL were co-expressed in lung cancer cell lines, and that Fas ligation induced by agonistic anti-Fas antibody is functional and induced apoptosis that was dependent on the levels of Fas expression. In contrast, Fas-FasL interactions appeared to be non-functional. Furthermore, our results suggest that cisplatin-induced apoptosis in lung cancer cells was independent of the Fas-FasL interaction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738132     DOI: 10.1016/s0959-8049(99)00332-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.

Authors:  Isaac Sipo; Almudena Hurtado Picó; Xiaomin Wang; Jürgen Eberle; Iver Petersen; Stefan Weger; Wolfgang Poller; Henry Fechner
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

2.  Anti-gastric cancer active immunity induced by FasL/B7-1 gene-modified tumor cells.

Authors:  Shi-Ying Zheng; De-Chun Li; Zhi-De Zhang; Jun Zhao; Jin-Feng Ge
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

3.  Pigment epithelial-derived factor (PEDF)-triggered lung cancer cell apoptosis relies on p53 protein-driven Fas ligand (Fas-L) up-regulation and Fas protein cell surface translocation.

Authors:  Lei Li; Ya-Chao Yao; Shu-Huan Fang; Cai-Qi Ma; Yi Cen; Zu-Min Xu; Zhi-Yu Dai; Cen Li; Shuai Li; Ting Zhang; Hong-Hai Hong; Wei-Wei Qi; Ti Zhou; Chao-Yang Li; Xia Yang; Guo-Quan Gao
Journal:  J Biol Chem       Date:  2014-09-15       Impact factor: 5.157

4.  Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells.

Authors:  D J A de Groot; T Timmer; D C J Spierings; T K P Le; S de Jong; E G E de Vries
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

Review 5.  Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy.

Authors:  Olivia A Diaz Arguello; Hidde J Haisma
Journal:  Cancers (Basel)       Date:  2021-03-27       Impact factor: 6.639

6.  Stellera chamaejasme L. extract induces apoptosis of human lung cancer cells via activation of the death receptor-dependent pathway.

Authors:  Xiaoni Liu; Xiaoxin Zhu
Journal:  Exp Ther Med       Date:  2012-07-20       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.